Cybin

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its Phase 2 trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (“MDD”), has completed dosing in Cohort 5 with no serious adverse events o.

Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their publication titled "Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS" in the journal Scientific Reports from the Nature.

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), underscores the ability of Kernel's Flow1 system to capture and analyze brain changes resulting from the administration of a psych.

Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

Atai Life Sciences BV

COMPASS Pathways

Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.

Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.

Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin.

Psychedelic Stocks: Don't Bet On Just 1 Company

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has commenced the development of a streamlined, scalable version of its EMBARK Training Program, known as EMBARKCT. The EMBARK psychedelic facilitator training program was launched in October 2021 and provides facilita.

Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin's Chief Medical Officer, will be participating in the upcoming PSYCH Symposium 2023 taking place Thursday, July 6, 2023 at the British Museum in London, UK. Dr. Inamdar.

Cybin to Participate in PSYCH Symposium London 2023

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the appointment of Aaron Bartlone as Chief Operating Officer of Cybin Inc., effective July 1, 2023. Mr. Bartlone has served as Chief Operating Officer of Cybin's U.S. subsidiary, Cybin US Holdings, Inc., since March 202.

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer

Aeglea BioTherapeutics

Amyris

Bionano Genomics

 Clene Nanomedicine

Clearmind Medicine Inc

Hyzon Motors

IronNet

NeuroBo Pharmaceuticals Inc

Qurate Retail Inc

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

10 Top Penny Stocks To Watch Right Now For Under $1

Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) reported that it has narrowed its net loss year-over-year as it has advanced its two lead clinical programs CYB003 and CYB004 during the 2023 fiscal year. For the fiscal year ended on March 31, 2023, the psychedelics-focused clinical-stage biopharmaceutical company posted a net loss of C$47.5 million, down from C$67.6 million in the previous fiscal year.

Cybin narrows net loss year-over-year; eyes FDA submission in late 2023

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported audited financial results for its fiscal year ended March 31, 2023, and recent business highlights. “During the past year, we have made significant progress advancing our two lead clinical programs, CYB003 and CYB004. We expect.

Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor. Mr. Climan is the CEO and founder of Entertainment Media Ventures, Inc., a Los Angeles based advisory and investment company specializing in identifyin.

Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat psychiatric and substance-use disorders and other medical conditions. Psychedelics are increasingly drawing attention from researchers, biotech companies and investors interested in their potential to help address the U.S. mental-health crisis.

FDA issues guidance on psychedelic drug clinical trials

The Beachbody Co.

Faraday Future Intelligent Electric

Canoo

Sidus Space

Sonnet BioTherapeutics

Vascular Biogenics

Versus Systems

Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.

Best Penny Stocks to Buy Under $1? 10 To Watch Now

Mind Medicine MindMed

Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.

TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, and Allison House-Gecewicz, Cybin's SVP of Clinical Operations, will be speaking at the Psychedelic Science 2023 Conference hosted the by Multidisciplinary Associatio.

Cybin to Participate in the 2023 MAPS Psychedelic Science Conference

Typically, we refer to stocks trading for less than $5 per share, as penny stocks. However, for this article, we're focusing specifically on penny stocks under $1.

Best Penny Stocks to Buy Under $1? 7 To Watch Now

Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1.

Best Penny Stocks to Buy Under $1? 4 To Watch Now

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference taking place on June 26, 2023. Mr. Drysdale's fireside chat w.

Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, provides a corporate update outlining access to capital and upcoming clinical milestones. “The second half of 2023 will be pivotal for Cybin as we expect topline clinical data readouts from both our Phase 1/2a trial of CYB003, our deuterated.

Cybin Inc. Provides Corporate Update

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced changes to its scientific management team. Following the achievement of the final milestones as contemplated by the terms of a contribution agreement dated December 4, 2020 between Cybin and Adelia Therapeutics Inc. (“Adelia”).

Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York City, NY from June 7-9, 2023. Mr. Drysdale's presentation will be webcast live on Friday,.

Cybin to Present at the Jefferies Healthcare Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has entered into a common share purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), an institutional investor. Subject to the terms and conditions of the Agreement, Cybin has the r.

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the first participants have been dosed with CYB004 in its ongoing three-part Phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers. As expected, robust psychedeli.

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. With the achievement of this milestone, Cybin intends.

News for Cybin Stock (CYBN)